Abstract
Biologics, including monoclonal antibodies, immune checkpoint inhibitors, and cytokine therapies, have revolutionized the landscape of oncology by offering novel approaches to cancer treatment. These therapies are designed to target specific molecular pathways involved in cancer cell proliferation and immune evasion, offering precision in targeting tumor cells while sparing normal tissues. This article evaluates the safety and efficacy of biologics in oncology, analyzing clinical trial data, patient outcomes, and the mechanisms of action of biologics in cancer treatment. Additionally, the challenges of toxicity, immune-related adverse events, and resistance mechanisms are explored, along with future directions for improving the therapeutic potential of biologics in oncology.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.